A seasoned PNW biotech operations and executive administration professional, Susie brings over 15 years of experience supporting C-suite executives, managing Board of Directors communications, and driving strategic initiatives in fast-paced, high-growth biotechnology environments. With a deep understanding of corporate governance, investor relations, regulatory compliance, and operational scaling, she has played a pivotal role in supporting local biotech companies through critical milestones, including initial startup, IPOs, FDA approvals, and acquisitions.
Most notably, Susie served as the Executive and Board of Directors Administrator at CTI BioPharma Corp., where she managed executive operations during a transformative period that included the FDA approval of VONJO® (pacritinib) for myelofibrosis and the company’s acquisition by Swedish Orphan Biovitrum (SOBI). Prior to CTI BioPharma, she held key operational and administrative roles at TwinStrand Biosciences (multi- NIH SBIR grant management) and NanoString Technologies, where she played a crucial role in the company’s pre-IPO and IPO phases, supporting the CFO (later Acting CEO) in financial operations and benefits administration, and corporate scaling—helping grow the company from 24 employees to over 450 globally during her tenure. Additional companies include Molecumetics, Koronis Pharmaceuticals, Harmoni Biosolutions, and consulting at Adaptive Biotechnologies with Westlake Consulting Group.
She holds a Bachelor of Arts in International Business from the University of Puget Sound and spent a year with NOAA working research ships in the Bering Sea and Antarctica. In her free time you’ll find her volunteering and running the exciting world of trail racing.